Intuitive Surgical Aktie News

To find stocks that can perform well over a decade or more, it's helpful to identify industries that seem to be on a long-term growth trajectory, then dig into the companies that lead these markets. In that spirit, let's look at two stocks that are among the dominant players in sectors with excellent prospects: Intuitive Surgical (ISRG -3.19%) and Amazon (AMZN -4.97%).

I'm invested in several healthcare stocks, and the one that I'm most excited about is Intuitive Surgical (ISRG -3.19%). The stock is down 15.5% year to date as I write this, making it more attractively priced than it was last year.

Franklin Street Advisors disclosed an exit from Intuitive Surgical (ISRG -0.92%) in its latest SEC filing for the quarter ended September 30, selling 42,601 shares for an estimated $23.2 million.

If you are a contrarian investor looking for investment ideas, one of the best places to start your search is the list of companies hitting 52-week lows. These are stocks that are, clearly, unloved by investors and, perhaps, the declines are also overdone.

FDA-cleared software release enhances navigation and broadens access to advanced imaging for lung biopsy procedures FDA-cleared software release enhances navigation and broadens access to advanced imaging for lung biopsy procedures

Shares of Intuitive Surgical (ISRG -0.59%) are down about 26% from a peak they set earlier this year. While 2025 hasn't been a great year to hold shares of the surgical robotics pioneer, there's a very good reason to watch it closely from now through the end of 2026.

Intuitive Surgical (ISRG 2.11%) stock has proven itself to be a winner for investors over time, advancing more than 700% over the past decade. This is thanks to the company's leadership in the high-growth market of robotic surgery and its ability to maintain that position and keep earnings roaring higher.

The medical sector in the United States has been heavily affected by a bearish cycle, driven by scandals surrounding the GLP-1 drugs used in weight loss solutions for consumers. As more companies are exposed to the manufacturing and distribution of these drugs, even some unrelated names have been dragged down by this broader sentiment, creating massive opportunities for those who are bold enoug...